NEW YORK (GenomeWeb) – Investment bank Rodman & Renshaw has initiated coverage of Nanosphere at a Buy rating and a 12-month price target of $2 per share.

The bank believes that Nanosphere's Verigene infectious disease identification system has the potential for significant sales growth. Rodman analyst Yi Chen wrote that the Verigene system and test panels are differentiated from competing systems because it's based on gold nanoparticle technology and doesn't use PCR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.